<?xml version='1.0' encoding='UTF-8'?>
<extracted-tables-set><pmcid/><all-ids><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid">PMC3674338</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcid-ver">PMC3674338.1</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaid">3674338</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmcaiid">3674338</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="pmid">23404139</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="doi">10.1007/s00330-013-2775-4</article-id><article-id xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" pub-id-type="publisher-id">2775</article-id></all-ids><extracted-table><table-id>Tab1</table-id><table-label>Table 1</table-label><table-caption>Demographic characteristics of the subjects</table-caption><table-wrap-foot>PD Parkinson’s disease, PDD Parkinson’s disease with dementia, MMSE Mini-Mental State Examination, NA not applicable, NS not significant (P &gt; 0.05)aMMSE scores were significantly lower in PDD patients than in controls (P &lt; 0.01) or PD patients (P &lt; 0.01), but the scores did not differ significantly between controls and PD patients</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab1" position="float" orientation="portrait"><label>Table 1</label><caption><p>Demographic characteristics of the subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">Control (<italic toggle="yes">n</italic> = 20)</th><th colspan="1" rowspan="1">PD (<italic toggle="yes">n</italic> = 20)</th><th colspan="1" rowspan="1">PDD (<italic toggle="yes">n</italic> = 20)</th><th colspan="1" rowspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td colspan="1" rowspan="1">Sex, male : female</td><td colspan="1" rowspan="1">10 : 10</td><td colspan="1" rowspan="1">8 : 12</td><td colspan="1" rowspan="1">10 : 10</td><td colspan="1" rowspan="1">NS</td></tr><tr><td colspan="1" rowspan="1">Age in years, mean (SD)</td><td colspan="1" rowspan="1">72.7 (3.3)</td><td colspan="1" rowspan="1">71.6 (4.3)</td><td colspan="1" rowspan="1">71.7 (5.3)</td><td colspan="1" rowspan="1">NS</td></tr><tr><td colspan="1" rowspan="1">Disease duration in months, mean (SD)</td><td colspan="1" rowspan="1">NA</td><td colspan="1" rowspan="1">94.0 (53.4)</td><td colspan="1" rowspan="1">146.6 (91.0)</td><td colspan="1" rowspan="1">&lt;0.05 (PD vs PDD)</td></tr><tr><td colspan="1" rowspan="1">Hoehn–Yahr stage (SD)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">2.4 (1.0)</td><td colspan="1" rowspan="1">2.9 (0.7)</td><td colspan="1" rowspan="1">&lt;0.05 (PD vs PDD)</td></tr><tr><td colspan="1" rowspan="1">MMSE (SD)<sup>a</sup></td><td colspan="1" rowspan="1">28.8</td><td colspan="1" rowspan="1">25.7 (3.2)</td><td colspan="1" rowspan="1">18.7 (5.8)</td><td colspan="1" rowspan="1">&lt;0.01 (PD vs PDD)</td></tr><tr><td colspan="1" rowspan="1">Levodopa dosage mg/day, median (SD)</td><td colspan="1" rowspan="1">0</td><td colspan="1" rowspan="1">464.2 (175.0)</td><td colspan="1" rowspan="1">673.3 (120.0)</td><td colspan="1" rowspan="1">&lt;0.05 (PD vs PDD)</td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">PD</italic> Parkinson’s disease, <italic toggle="yes">PDD</italic> Parkinson’s disease with dementia, <italic toggle="yes">MMSE</italic> Mini-Mental State Examination, <italic toggle="yes">NA</italic> not applicable, <italic toggle="yes">NS</italic> not significant (<italic toggle="yes">P</italic> &gt; 0.05)</p><p><sup>a</sup>MMSE scores were significantly lower in PDD patients than in controls (<italic toggle="yes">P</italic> &lt; 0.01) or PD patients (<italic toggle="yes">P</italic> &lt; 0.01), but the scores did not differ significantly between controls and PD patients</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 1<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Demographic characteristics of the subjects</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>Control (n = 20)</th><th>PD (n = 20)</th><th>PDD (n = 20)</th><th>P value</th></tr></thead><tbody><tr><td>Sex, male : female</td><td>10 : 10</td><td>8 : 12</td><td>10 : 10</td><td>NS</td></tr><tr><td>Age in years, mean (SD)</td><td>72.7 (3.3)</td><td>71.6 (4.3)</td><td>71.7 (5.3)</td><td>NS</td></tr><tr><td>Disease duration in months, mean (SD)</td><td>NA</td><td>94.0 (53.4)</td><td>146.6 (91.0)</td><td>&lt;0.05 (PD vs PDD)</td></tr><tr><td>Hoehn–Yahr stage (SD)</td><td>0</td><td>2.4 (1.0)</td><td>2.9 (0.7)</td><td>&lt;0.05 (PD vs PDD)</td></tr><tr><td>MMSE (SD)a</td><td>28.8</td><td>25.7 (3.2)</td><td>18.7 (5.8)</td><td>&lt;0.01 (PD vs PDD)</td></tr><tr><td>Levodopa dosage mg/day, median (SD)</td><td>0</td><td>464.2 (175.0)</td><td>673.3 (120.0)</td><td>&lt;0.05 (PD vs PDD)</td></tr></tbody></table></div>PD Parkinson’s disease, PDD Parkinson’s disease with dementia, MMSE Mini-Mental State Examination, NA not applicable, NS not significant (P &gt; 0.05)aMMSE scores were significantly lower in PDD patients than in controls (P &lt; 0.01) or PD patients (P &lt; 0.01), but the scores did not differ significantly between controls and PD patients</transformed-table></extracted-table><extracted-table><table-id>Tab2</table-id><table-label>Table 2</table-label><table-caption>Comparison of mean diffusivity (MD) and fractional anisotropy (FA) in the genu of the corpus callosum in patients and control subjects</table-caption><table-wrap-foot>GCC genu of the corpus callosum, PD Parkinson’s disease, PDD Parkinson’s disease with dementia, CN control subjectsaValues are means ± standard deviationbDiffusivity values are expressed as 10−3 mm2/scStatistical significance (P &lt; 0.05)</table-wrap-foot><original-table><table-wrap xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" id="Tab2" position="float" orientation="portrait"><label>Table 2</label><caption><p>Comparison of mean diffusivity (MD) and fractional anisotropy (FA) in the genu of the corpus callosum in patients and control subjects</p></caption><table frame="hsides" rules="groups"><thead><tr><th colspan="1" rowspan="1"/><th colspan="1" rowspan="1">CN</th><th colspan="1" rowspan="1">PD</th><th colspan="1" rowspan="1">PDD</th><th colspan="3" rowspan="1"/></tr></thead><tbody><tr><td colspan="1" rowspan="1">GCC</td><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">CN &gt; PD</td><td colspan="1" rowspan="1">CN &gt; PDD</td><td colspan="1" rowspan="1">PD &gt; PDD</td></tr><tr><td colspan="1" rowspan="1">FA</td><td colspan="1" rowspan="1">0.52 ± 0.03<sup>a</sup></td><td colspan="1" rowspan="1">0.52 ± 0.03</td><td colspan="1" rowspan="1">0.49 ± 0.04</td><td colspan="1" rowspan="1">NS</td><td colspan="1" rowspan="1"><italic toggle="yes">P</italic> &lt; 0.005<sup>c</sup></td><td colspan="1" rowspan="1"><italic toggle="yes">P</italic> &lt; 0.005<sup>c</sup></td></tr><tr><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1"/><td colspan="1" rowspan="1">CN &lt; PD</td><td colspan="1" rowspan="1">CN &lt; PDD</td><td colspan="1" rowspan="1">PD &lt; PDD</td></tr><tr><td colspan="1" rowspan="1">MD<sup>b</sup></td><td colspan="1" rowspan="1">1.01 ± 0.07</td><td colspan="1" rowspan="1">1.04 ± 0.08</td><td colspan="1" rowspan="1">1.13 ± 0.10</td><td colspan="1" rowspan="1">NS</td><td colspan="1" rowspan="1"><italic toggle="yes">P</italic> &lt; 0.00014<sup>c</sup></td><td colspan="1" rowspan="1"><italic toggle="yes">P</italic> &lt; 0.0013<sup>c</sup></td></tr></tbody></table><table-wrap-foot><p><italic toggle="yes">GCC</italic> genu of the corpus callosum, <italic toggle="yes">PD</italic> Parkinson’s disease, <italic toggle="yes">PDD</italic> Parkinson’s disease with dementia, <italic toggle="yes">CN</italic> control subjects</p><p><sup>a</sup>Values are means ± standard deviation</p><p><sup>b</sup>Diffusivity values are expressed as 10<sup>−3</sup> mm<sup>2</sup>/s</p><p><sup>c</sup>Statistical significance (<italic toggle="yes">P</italic> &lt; 0.05)</p></table-wrap-foot></table-wrap></original-table><transformed-table>Table 2<div xmlns="http://www.w3.org/1999/xhtml" class="caption">Comparison of mean diffusivity (MD) and fractional anisotropy (FA) in the genu of the corpus callosum in patients and control subjects</div><div xmlns="http://www.w3.org/1999/xhtml" class="table"><table frame="hsides" rules="groups"><thead><tr><th/><th>CN</th><th>PD</th><th>PDD</th><th colspan="3"/></tr></thead><tbody><tr><td>GCC</td><td/><td/><td/><td>CN &gt; PD</td><td>CN &gt; PDD</td><td>PD &gt; PDD</td></tr><tr><td>FA</td><td>0.52 ± 0.03a</td><td>0.52 ± 0.03</td><td>0.49 ± 0.04</td><td>NS</td><td>P &lt; 0.005c</td><td>P &lt; 0.005c</td></tr><tr><td/><td/><td/><td/><td>CN &lt; PD</td><td>CN &lt; PDD</td><td>PD &lt; PDD</td></tr><tr><td>MDb</td><td>1.01 ± 0.07</td><td>1.04 ± 0.08</td><td>1.13 ± 0.10</td><td>NS</td><td>P &lt; 0.00014c</td><td>P &lt; 0.0013c</td></tr></tbody></table></div>GCC genu of the corpus callosum, PD Parkinson’s disease, PDD Parkinson’s disease with dementia, CN control subjectsaValues are means ± standard deviationbDiffusivity values are expressed as 10−3 mm2/scStatistical significance (P &lt; 0.05)</transformed-table></extracted-table></extracted-tables-set>